Related Experiment Video

Updated: May 26, 2026

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
11:38

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay

Published on: September 14, 2021

Transforming growth factor-β/Smad signalling in diabetic nephropathy

Hui Yao Lan1

  • 1Li Ka Shing Institute of Health Sciences and Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. hylan@cuhk.edu.hk

Clinical and Experimental Pharmacology & Physiology
|January 4, 2012
PubMed

Insights

Diabetic nephropathy (DN) involves transforming growth factor-β1 (TGF-β1) signaling. Targeting Smad proteins and related microRNAs offers a promising therapeutic strategy for DN treatment.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Diabetology

Background:

  • Diabetic nephropathy (DN) is a significant complication of diabetes.
  • Transforming growth factor-β1 (TGF-β1) signaling, particularly via Smad proteins, is central to DN pathogenesis.
  • Profibrotic factors activate Smad pathways through cross-talk with other signaling cascades.

Purpose of the Study:

  • To elucidate the roles of Smad proteins (Smad2, Smad3, Smad7) in diabetic nephropathy.
  • To investigate the involvement of microRNAs in TGF-β1/Smad signaling during renal fibrosis.
  • To explore potential therapeutic strategies targeting the TGF-β/Smad pathway for DN treatment.

Main Methods:

  • Analysis of Smad-dependent and -independent signaling pathways in DN.
  • Investigation of Smad3's pathogenic and Smad2's protective roles in renal fibrosis.
  • Examination of Smad7's protective function against renal fibrosis and inflammation.
  • Assessment of microRNA expression profiles (miR-21, miR-192, miR-29, miR-200) regulated by TGF-β1/Smad3.

Main Results:

  • Smad3 deletion inhibits renal fibrosis, while Smad2 disruption promotes it.
  • Smad7 overexpression protects against Smad3-mediated fibrosis and NF-κB-driven inflammation.
  • TGF-β1 activates Smad3, altering microRNA expression: upregulation of miR-21/miR-192 and downregulation of miR-29/miR-200 families.
  • These microRNAs mediate renal fibrosis in DN.

Conclusions:

  • Smad proteins are key regulators in DN, with differential roles for Smad2 and Smad3.
  • Smad7 acts protectively in DN by inhibiting fibrosis and inflammation.
  • MicroRNAs regulated by TGF-β1/Smad3 signaling are critical mediators of DN-associated fibrosis.
  • Targeting downstream TGF-β/Smad signaling, including Smad7 and specific microRNAs, presents a novel therapeutic avenue for DN.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...